Kura Oncology, Inc. — Fiscal 2016 Form 10-K Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision oncology medicines and companion diagnostics. This Form 10-K covers the fiscal year ended December 31, 2016 and was filed March 14, 2017. The company had no approved products or product revenue and employed 22 full-time and three part-time employees at year-end.
- Tipifarnib: Lead oral farnesyl transferase inhibitor in four Phase 2 programs: HRAS-mutant solid tumors, peripheral T-cell lymphoma, lower-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.
- KO-947: ERK inhibitor; FDA investigational new drug application became effective in December 2016, with Phase 1 initiation planned for the first half of 2017.
- KO-539: Menin-MLL inhibitor; nominated as a development candidate in December 2016 and remained preclinical.
Financial performance and key metrics
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No change |
| Research and development expense | $20.4 million | $17.8 million | +$2.6 million |
| General and administrative expense | $8.0 million | $6.1 million | +$1.9 million |
| Other income, net | $0.8 million | $1.2 million | -$0.4 million |
| Net loss | $27.6 million | $22.6 million | +$4.9 million loss |
| Basic and diluted loss per share | $1.47 | $2.28 | Improved due primarily to higher share count |
| Net cash used in operating activities | $25.3 million | $17.9 million | +$7.4 million use |
| Cash, cash equivalents and short-term investments | $67.8 million | $85.7 million | -$17.9 million |
| Long-term debt, net | $7.3 million | $0 | New debt facility |
Gross or operating margins are not meaningful because the company had no product sales. Total operating expenses were $28.4 million in 2016 versus $23.9 million in 2015. Accumulated deficit increased to $53.9 million from $26.3 million.
Research and development spending increased for tipifarnib by $3.4 million, primarily because of Phase 2 clinical development and manufacturing. KO-947 spending declined by $2.1 million as IND-enabling activities were completed, while discovery and preclinical spending increased by $1.6 million, mainly for the menin-MLL program.
Liquidity, debt and capital resources
- Year-end cash and cash equivalents were $9.7 million, with $58.1 million of short-term investments.
- Operating cash use increased to $25.3 million. Investing activities provided $12.2 million, primarily from net maturities of marketable securities.
- In April 2016, Kura borrowed $7.5 million under a term loan facility of up to $20.0 million. An additional $12.5 million was available through May 1, 2017, subject to advancement of KO-947 into Phase 1.
- The term loan bears interest at 7.75% at December 31, 2016, is interest-only through May 1, 2018, and matures November 1, 2020. It is secured by substantially all assets other than intellectual property and includes restrictive covenants, warrants and potential final-payment and unused-capacity fees.
- Management expected existing resources, including available financing, to fund current operations into the second half of 2018, but stated that substantial additional financing would be required thereafter.
- In January 2017, Kura established an at-the-market facility permitting sales of up to $25.0 million of common stock; no shares had been sold under the facility as of the filing.
Material changes, outlook and unusual items
- The company expanded and advanced its clinical pipeline, including initiation of the lower-risk MDS and CMML Phase 2 studies and nomination of KO-539.
- Management expected additional HRAS-mutant solid tumor and PTCL data in 2017 and MDS and CMML data in the first half of 2018. A registrational tipifarnib trial would depend on supportive Phase 2 results.
- Tipifarnib’s composition-of-matter patents had expired in the United States and Europe in 2016. Future commercial protection depends on method-of-use or other intellectual property and potential regulatory exclusivity.
- The company reported no material legal proceedings and no off-balance-sheet arrangements.
- Related-party transactions included research and development services from Wellspring, management services provided to Araxes, and a $100,000 milestone payment to Araxes upon filing the KO-947 IND.
- The filing states that KO-947 manufacturing and formulation work had experienced delays, including development of a lyophilized formulation after the initial intravenous formulation did not meet stability specifications.
Principal risks and contingencies
- Continued losses, negative operating cash flow and dependence on additional equity, debt, collaboration or licensing financing.
- Uncertainty regarding clinical efficacy, safety, patient enrollment, dose optimization, regulatory approval and the development of companion diagnostics.
- Tipifarnib’s prior lack of sufficient efficacy for FDA approval, limited remaining composition-of-matter patent protection and dependence on licensed rights from Janssen.
- Reliance on third-party contract research organizations, manufacturers, suppliers and diagnostic partners.
- Debt covenants, secured lender claims, potential dilution from equity financing, stock options and warrants, and possible acceleration upon default.
- Competition from established cancer therapies and other targeted drug candidates, as well as reimbursement, pricing and healthcare-policy uncertainty.
Important facts for investors to verify
- Actual cash runway after considering operating cash burn, the $12.5 million contingent loan tranche and any use of the $25.0 million ATM facility.
- Enrollment status, efficacy, durability and safety results from each tipifarnib Phase 2 program and the timing of any registrational trial.
- Whether KO-947 entered Phase 1 on schedule and whether formulation or manufacturing issues affected development.
- The scope, validity and remaining term of patent, method-of-use and regulatory protections for tipifarnib, KO-947 and KO-539.
- Potential dilution and covenant effects from future equity issuance, additional debt, warrants and equity incentive plans.
- Whether biomarker and companion-diagnostic strategies can identify sufficiently large, responsive patient populations.